Abstract
Esophageal Cancer Radiotherapy Dose Escalation Meta Regression Commentary: “High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis”
Highlights
Esophageal cancer is one of the most common and lethal cancers in the world, with 600,000 cases and accounting for 544,000 cause-specific mortalities in 2020 [1]
We commend the authors for a thorough and informative study that helps to inform radiation dosing for non-operable patients
Study data on overall survival (OS), local-regional failure rate and distant metastasis rate were extracted, and cross-validated with that reported by Sun et al [9]
Summary
Esophageal cancer is one of the most common and lethal cancers in the world, with 600,000 cases and accounting for 544,000 cause-specific mortalities in 2020 [1]. Been initiated, assessing the role of dose escalation for patients receiving definitive radiotherapy [4,5,6,7]. Sun et al recently conducted a systematic review and meta-analysis comparing high-dose radiotherapy to standard-dose radiotherapy in the setting of definitive concurrent chemoradiotherapy for esophageal cancer [9]. With the pooled sample size across 12 studies and greater statistical power, they reported superior OS and local-regional control rates for patients receiving high-dose radiotherapy, and no difference in distant metastasis rate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.